Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Dimitri P. Mikhailidis, Richard W. Lawson, Anna-Louise McCormick, Gillian C. Sibbring, Andrew M. Tershakovec, Glenn M. Davies & Kaan Tunceli. (2011) Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Current Medical Research and Opinion 27:6, pages 1191-1210.
Read now
Read now
Nkechinyere Ijioma & Jennifer G Robinson. (2011) Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy 9:2, pages 131-145.
Read now
Read now
L. Nherera, N.W. Calvert, K. DeMott, S.E. Humphries, H.A.W. Neil, R. Minhas & M. Thorogood. (2010) Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Current Medical Research and Opinion 26:3, pages 529-536.
Read now
Read now
Scott L. Charland & Daniel C. Malone. (2010) Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research and Opinion 26:2, pages 365-375.
Read now
Read now
I. Migdalis, A. Efthimiadis, St. Pappas, D. Alexopoulos, F. Vlasserou & D. P. Mikhailidis. (2009) Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Current Medical Research and Opinion 25:10, pages 2571-2576.
Read now
Read now
Zlatko Fras & Dimitri P Mikhailidis. (2008) Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Current Medical Research and Opinion 24:9, pages 2467-2476.
Read now
Read now
D. P. Mikhailidis, G. C. Sibbring, C. M. Ballantyne, G. M. Davies & A. L. Catapano. (2007) Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current Medical Research and Opinion 23:8, pages 2009-2026.
Read now
Read now
Irene F Gazi & Dimitri P Mikhailidis. (2006) Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opinion on Therapeutic Targets 10:6, pages 851-866.
Read now
Read now
Alberico L. Catapano, Michael H. Davidson, Christie M. Ballantyne, William E. Brady, Russell A. Gazzara, Joanne E. Tomassini & Andrew M. Tershakovec. (2006) Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Current Medical Research and Opinion 22:10, pages 2041-2053.
Read now
Read now
Articles from other publishers (27)
Zahra Lotfollahi, Ana P. Q. Mello, Francisco A. H. Fonseca, Luciene O. Machado, Andressa F. Mathias, Maria C. Izar, Nagila R. T. Damasceno, Cristiano L. P. Oliveira & Antônio M. F. Neto. (2022) Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction. PLOS ONE 17:8, pages e0273292.
Crossref
Crossref
Christie M. Ballantyne & Alberico L. Catapano. (2022) The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. European Atherosclerosis Journal 1:1, pages 2-13.
Crossref
Crossref
Angela Pirillo, Giuseppe D. Norata & Alberico L. Catapano. 2020.
J. D. Kobalava, V. S. Gurevich, A. M. Galyavich, A. I. Kaminnyi, V. V. Kashtalap, V. Yu. Mareev, A. V. Susekov & I. I. Shaposhnik. (2019) Possibilities of clinical use of ezetimibe Otrio (JSC “AKRIKHIN”, Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts. Kardiologiia 59:5S, pages 47-57.
Crossref
Crossref
David Karásek. (2019) Ezetimibe in the treatment of hypercholesterolaemia. Interní medicína pro praxi 21:2, pages 112-116.
Crossref
Crossref
Yongming Liu, Nan Xia, Wanying Hu & Wei Zhao. (2019) Lipid-altering Efficacy of Ezetimibe/Simvastatin Compared with
Rosuvastatin in Hypercholesterolaemic Patients: A Meta-Analysis. International Journal of Pharmacology 15:2, pages 200-208.
Crossref
Crossref
David Karásek. (2018) Combined lipid-lowering therapy. Vnitřní lékařství 64:12, pages 1177-1184.
Crossref
Crossref
Woohyeun Kim, Yeonyee E. Yoon, Sung-Hee Shin, Jang-Whan Bae, Bum-Kee Hong, Soon Jun Hong, Ki Chul Sung, Seung Hwan Han, Weon Kim, Moo-Yong Rhee, Sang-Hyun Kim, Sang Eun Lee, Min Su Hyon, Gyo-Seung Hwang, Jang Won Son, Jang-Young Kim, Min Kyu Kim, Sang Wook Kim, Jae-Hyeong Park, Jin Ho Shin & Chang Gyu Park. (2018) Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clinical Therapeutics 40:6, pages 993-1013.
Crossref
Crossref
Michele Massimo Gulizia, Furio Colivicchi, Gualtiero Ricciardi, Simona Giampaoli, Aldo Pietro Maggioni, Maurizio Averna, Maria Stella Graziani, Ferruccio Ceriotti, Alessandro Mugelli, Francesco Rossi, Gerardo Medea, Damiano Parretti, Maurizio Giuseppe Abrignani, Marcello Arca, Pasquale Perrone Filardi, Francesco Perticone, Alberico Catapano, Raffaele Griffo, Federico Nardi, Carmine Riccio, Andrea Di Lenarda, Marino Scherillo, Nicoletta Musacchio, Antonio Vittorio Panno, Giovanni Battista Zito, Mauro Campanini, Leonardo Bolognese, Pompilio Massimo Faggiano, Giuseppe Musumeci, Enrico Pusineri, Marcello Ciaccio, Enzo Bonora, Giorgio Cantelli Forti, Maria Pia Ruggieri, Claudio Cricelli, Francesco Romeo, Roberto Ferrari & Attilio Maseri. (2017) ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy. European Heart Journal Supplements 19:suppl_D, pages D3-D54.
Crossref
Crossref
A. Pirillo, G.D. Norata & A.L. Catapano. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
663
693
.
Lisandro Damián Colantonio, Emilio Carlos Cermignani, Agustín Ciapponi & Juan I Calcagno. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
A. B. Sumarokov & V. V. Kukharchuk. (2014) Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia. Terapevticheskii arkhiv 86:12, pages 107.
Crossref
Crossref
Yue Qi, Jing Liu, Changsheng Ma, Wei Wang, Xiaohui Liu, Miao Wang, Qiang Lv, Jiayi Sun, Jun Liu, Yan Li & Dong Zhao. (2013) Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. Journal of Lipid Research 54:11, pages 3189-3197.
Crossref
Crossref
Ming-Hui ChenJoseph G. IbrahimArvind K. ShahJianxin LinHui Yao. (2012) Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs. Statistics in Medicine 31:28, pages 3597-3616.
Crossref
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Ezetimibe – a new approach in hypercholesterolemia management. Pharmacological Reports 64:4, pages 997-998.
Crossref
Crossref
E. Moutzouri, E. Liberopoulos, D. P. Mikhailidis, M. S. Kostapanos, A. A. Kei, H. Milionis & M. Elisaf. (2011) Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. International Journal of Clinical Practice 65:11, pages 1141-1148.
Crossref
Crossref
E. Bruckert, M. Farnier & J. Ferrières. (2010) HDL-cholestérol et risque cardiovasculaire : au-delà du LDL !. Médecine des Maladies Métaboliques 4:4, pages 379-388.
Crossref
Crossref
Michalis Kalogirou, Vasilis Tsimihodimos & Moses Elisaf. (2010) Pleiotropic effects of ezetimibe: Do they really exist?. European Journal of Pharmacology 633:1-3, pages 62-70.
Crossref
Crossref
C. Lucioni, S. Mazzi, M. Fagotti, P. Fondi & M. B. Goretti. (2013) Valutazione di un risultato del trattamento con statine: il caso dell’ASL di Foligno (PG)An evaluation of statin treatment results. PharmacoEconomics Italian Research Articles 10:3, pages 123-136.
Crossref
Crossref
Mathias H Konstandin, Erwin Blessing, Andreas Doesch, Kerstin Ammon, Achim Koch, Guido H Wabnitz, Christian A Gleissner, Andrew Remppis, Hugo A Katus & Thomas J Dengler. (2008) Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. Clinical Transplantation 22:5, pages 639-644.
Crossref
Crossref
C. Lucioni, S. Mazzi, B. Pari, M. Bonello, B. Mazzanti, G. Fresca, M. Fagotti, M. B. Goretti, G. Rossi, G. E. Giuliani, L. Patregnani, C. Bogino, M. D’Orsi, M. Tinella & G. F. Zuccotti. (2013) L’utilizzo delle DDD reference based per la valutazione della compliance terapeutica nel trattamento con statineTreatment with statins. Compliance evaluation using reference based DDDs. PharmacoEconomics Italian Research Articles 10:2, pages 77-88.
Crossref
Crossref
Michael H. Davidson & Jennifer G. Robinson. (2007) Safety of Aggressive Lipid Management. Journal of the American College of Cardiology 49:17, pages 1753-1762.
Crossref
Crossref
Ronald B. Goldberg, John R. Guyton, Theodore Mazzone, Ruth S. Weinstock, Adam Polis, Patricia Edwards, Joanne E. Tomassini & Andrew M. Tershakovec. (2006) Ezetimibe/Simvastatin vs Atorvastatin in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia: The VYTAL Study. Mayo Clinic Proceedings 81:12, pages 1579-1588.
Crossref
Crossref
Fides Benfatti, Giuliana Cardillo, Luca Gentilucci, Rossana Perciaccante, Alessandra Tolomelli & Alberico Catapano. (2006) Synthesis and Biological Evaluation of Azido- and Aziridino-hydroxyl-β-lactams through Stereo- and Regioselective Epoxide Ring Opening. The Journal of Organic Chemistry 71:24, pages 9229-9232.
Crossref
Crossref
Lisandro Damián Colantonio, Emilio Carlos Cermignani & Agustín Ciapponi. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Gilbert Thompson, Jonathan Morrell, Peter Wilson & Antonio Gotto. 2006. Dyslipidaemia in Clinical Practice, Second Edition. Dyslipidaemia in Clinical Practice, Second Edition
75
90
.
Michel R. Hoenig, Barbara E. Rolfe & Julie H. Campbell. (2006) Cholestanol: A serum marker to guide LDL cholesterol-lowering therapy. Atherosclerosis 184:2, pages 247-254.
Crossref
Crossref